PYC Therapeutics (ASX:PYC)
ASX announcement history & article coverage
Transparent by design.
Announcments by PYC Therapeutics (ASX:PYC) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Grant of Patents by the US Patent Office
Appointment of Chief Financial Officer
Notification of cessation of securities - PYC
Becoming a substantial holder
Company Secretary Appointment/Resignation
Notice of General Meeting/Proxy Form
Change to CEO remuneration
2026 Q2 Investor Webinar Presentation
Ceasing to be a substantial holder
Investor Webinar
Notification of cessation of securities - PYC
PKD - Initiation of Multiple Dose Clinical Trial
PYC Therapeutics Starts Phase 1b Trial for PKD Drug Candidate PYC-003
Presentation of Ophthalmology Clinical Trial Data at ARVO
PYC Therapeutics presents promising Phase 1/2 data for RNA therapies targeting childhood blinding eye diseases at ARVO 2026
Exercise of Options and Cleansing Notice
Application for quotation of securities - PYC
Quarterly Activities/Appendix 4C Cash Flow Report
PYC Therapeutics advances clinical pipeline and raises $600m capital in Q1 2026 update
Orphan Drug Designation Granted for RP11 by EMA
PYC Therapeutics' RP11 Drug Candidate Receives EMA Orphan Drug Designation
ADOA Program - SRC Approve Progression to Multi-Dose Study
PYC Therapeutics Advances PYC-001 to Multiple Dose Study for Blinding Eye Disease ADOA
